ELMSFORD, NY / ACCESSWIRE / March 20, 2019 / NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company
utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced it has
entered into an exclusive agreement with N.B.A. medica s.r.l. to market and distribute NanoVibronix's PainShield® and UroShield in
Italy.
N.B.A. medica s.r.l. is a leading distributor of medical equipment in Italy, with an established European distribution network
that includes international sub distributors, public hospitals, private clinics, sports medicine centers, nursing homes, and
leading health websites. N.B.A medica represents many of the premier global medical device companies within Italy. Additional
information is available at http://www.nbamedica.it.
Marco Sesenna, CEO of N.B.A. medica, stated, "We are excited to partner with NanoVibronix to market and distribute PainShield
and UroShield in Italy. Based on an exhaustive review of the clinical data, as well as our own initial market research and
discussions with key opinion leaders, we believe there is significant market potential for these devices within Italy."
Brian Murphy, CEO of NanoVibronix, commented, "N.B.A. medica is an ideal partner as they bring over 70 years of experience and
an established distribution network that spans a variety of sales channels. This latest agreement marks another important milestone
as we rapidly expand our presence across Europe."
PainShield and UroShield are ultrasound devices each consisting of a reusable driver unit and a disposable patch, which contains
a proprietary therapeutic transducer. PainShield delivers a localized ultrasound effect to treat pain and induce soft tissue
healing in a targeted area, while keeping the level of ultrasound energy at a safe and consistent level. UroShield is a device
intended to prevent bacterial colonization and biofilm formation, and ultimately helping to prevent catheter associated urinary
tract infections. Its range of applications includes acute and chronic pain resolution through its many mechanisms of action.
PainShield, which has broad applications for sports injuries, has been acknowledged by several sports icons. PainShield can be used
by patients at home or work or in a clinical setting and can be used even while the patient is sleeping. Patient benefits noted in
clinical studies include ease of application and use, faster recovery time, high compliance, and mechanisms of action that affect
soft tissue repair. Patients using UroShield have shown a significantly less incidence of UTI, pain, and an increase in antibiotic
effectiveness.
About NanoVibronix
NanoVibronix Inc. (NASDAQ: NAOV) is a medical device company headquartered in Elmsford,
NY with research and development in Nesher, Israel, that is focused on developing medical devices utilizing its proprietary and
patented low intensity surface acoustic wave technology. The company's technology allows for the creation of low-frequency
ultrasound waves that can be utilized for a variety of medical applications, including the disruption of biofilms and bacteria
colonization, as well as providing pain relief. The devices can be administered at home without the assistance of medical
professionals. The company's primary products include PainShield®, UroShield™ and WoundShield™. Additional information about the
company is available at: www.nanovibronix.com.
Forward-looking Statements
This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may,"
"will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar
words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to
various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or
quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking
statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance
of our existing and new products or lengthy product delays in key markets; (ii) negative or unreliable clinical trial results (iii)
an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry
from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing
capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and
other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection
covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S.
and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need
to raise additional capital to meet our business requirements in the future and that such capital may not be available, or may be
costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us
to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with
foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk
factors that may affect the realization of forward looking statements is set forth in the Company’s filings with the Securities and
Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and
security holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov. The Company assumes
no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or
otherwise.
Investor Contacts:
Crescendo Communications
naov@crescendo-ir.com
(212) 671-1021
SOURCE: NanoVibronix, Inc.
